vs
AMERICAN SHARED HOSPITAL SERVICES（AMS）与GRAIL, Inc.（GRAL）财务数据对比。点击上方公司名可切换其他公司
GRAIL, Inc.的季度营收约是AMERICAN SHARED HOSPITAL SERVICES的5.6倍（$43.6M vs $7.7M）。AMERICAN SHARED HOSPITAL SERVICES净利率更高（-8.2% vs -227.5%，领先219.3%）。GRAIL, Inc.同比增速更快（14.0% vs -14.8%）。AMERICAN SHARED HOSPITAL SERVICES自由现金流更多（$-2.7M vs $-63.9M）。过去两年GRAIL, Inc.的营收复合增速更高（27.7% vs 21.7%）
美国共享医院服务公司为医疗机构提供放射治疗、立体定向放射外科及诊断成像设备的整体外包解决方案，免除医院高昂的前期资本投入，主要业务覆盖北美，同时服务拉美及部分亚太地区的公立、私立医院客户。
GRAIL是2015年成立的美国生物技术企业，总部位于加利福尼亚州门洛帕克，核心业务是研发面向无症状人群的癌症早期筛查检测产品。该公司最初是基因测序企业Illumina旗下的初创子公司，2021年被Illumina全资收购。
AMS vs GRAL — 直观对比
营收规模更大
GRAL
是对方的5.6倍
$7.7M
营收增速更快
GRAL
高出28.8%
-14.8%
净利率更高
AMS
高出219.3%
-227.5%
自由现金流更多
AMS
多$61.2M
$-63.9M
两年增速更快
GRAL
近两年复合增速
21.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $7.7M | $43.6M |
| 净利润 | $-631.0K | $-99.2M |
| 毛利率 | 11.7% | — |
| 营业利润率 | -18.1% | -285.4% |
| 净利率 | -8.2% | -227.5% |
| 营收同比 | -14.8% | 14.0% |
| 净利润同比 | 52.5% | -2.2% |
| 每股收益（稀释后） | $-0.09 | $-2.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSGRAL
| Q4 25 | $7.7M | $43.6M | ||
| Q3 25 | $7.2M | $36.2M | ||
| Q2 25 | $7.1M | $35.5M | ||
| Q1 25 | $6.1M | $31.8M | ||
| Q4 24 | $9.1M | $38.3M | ||
| Q3 24 | $7.0M | $28.7M | ||
| Q2 24 | $7.1M | $32.0M | ||
| Q1 24 | $5.2M | $26.7M |
净利润AMSGRAL
| Q4 25 | $-631.0K | $-99.2M | ||
| Q3 25 | $-17.0K | $-89.0M | ||
| Q2 25 | $-280.0K | $-114.0M | ||
| Q1 25 | $-625.0K | $-106.2M | ||
| Q4 24 | $-1.3M | $-97.1M | ||
| Q3 24 | $-207.0K | $-125.7M | ||
| Q2 24 | $3.6M | $-1.6B | ||
| Q1 24 | $119.0K | $-218.9M |
毛利率AMSGRAL
| Q4 25 | 11.7% | — | ||
| Q3 25 | 22.1% | — | ||
| Q2 25 | 23.1% | — | ||
| Q1 25 | 15.4% | — | ||
| Q4 24 | 35.3% | — | ||
| Q3 24 | 19.6% | — | ||
| Q2 24 | 35.0% | — | ||
| Q1 24 | 41.1% | — |
营业利润率AMSGRAL
| Q4 25 | -18.1% | -285.4% | ||
| Q3 25 | -4.8% | -346.2% | ||
| Q2 25 | -7.7% | -446.9% | ||
| Q1 25 | -21.3% | -482.5% | ||
| Q4 24 | -20.2% | -358.0% | ||
| Q3 24 | -12.7% | -640.5% | ||
| Q2 24 | -0.0% | -5133.8% | ||
| Q1 24 | -1.6% | -851.1% |
净利率AMSGRAL
| Q4 25 | -8.2% | -227.5% | ||
| Q3 25 | -0.2% | -245.8% | ||
| Q2 25 | -4.0% | -320.7% | ||
| Q1 25 | -10.2% | -333.6% | ||
| Q4 24 | -14.6% | -253.8% | ||
| Q3 24 | -3.0% | -438.7% | ||
| Q2 24 | 51.0% | -4958.8% | ||
| Q1 24 | 2.3% | -819.3% |
每股收益（稀释后）AMSGRAL
| Q4 25 | $-0.09 | $-2.37 | ||
| Q3 25 | $0.00 | $-2.46 | ||
| Q2 25 | $-0.04 | $-3.18 | ||
| Q1 25 | $-0.10 | $-3.10 | ||
| Q4 24 | $-0.21 | $-1.49 | ||
| Q3 24 | $-0.03 | $-3.94 | ||
| Q2 24 | $0.55 | $-51.06 | ||
| Q1 24 | $0.02 | $-7.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5M | $249.7M |
| 总债务越低越好 | $17.4M | — |
| 股东权益账面价值 | $24.0M | $2.6B |
| 总资产 | $55.5M | $2.9B |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势，按日历期对齐
现金及短期投资AMSGRAL
| Q4 25 | $3.5M | $249.7M | ||
| Q3 25 | $5.1M | $126.9M | ||
| Q2 25 | $11.1M | $127.4M | ||
| Q1 25 | $11.2M | $133.9M | ||
| Q4 24 | $11.0M | $214.2M | ||
| Q3 24 | $13.8M | $853.6M | ||
| Q2 24 | $14.2M | $958.8M | ||
| Q1 24 | $12.8M | $199.7M |
总债务AMSGRAL
| Q4 25 | $17.4M | — | ||
| Q3 25 | $18.2M | — | ||
| Q2 25 | $19.1M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | $20.4M | — | ||
| Q3 24 | $14.4M | — | ||
| Q2 24 | $15.1M | — | ||
| Q1 24 | $15.6M | — |
股东权益AMSGRAL
| Q4 25 | $24.0M | $2.6B | ||
| Q3 25 | $24.6M | $2.2B | ||
| Q2 25 | $24.5M | $2.3B | ||
| Q1 25 | $24.6M | $2.4B | ||
| Q4 24 | $25.2M | $2.5B | ||
| Q3 24 | $26.4M | $2.6B | ||
| Q2 24 | $26.5M | $2.7B | ||
| Q1 24 | $22.8M | — |
总资产AMSGRAL
| Q4 25 | $55.5M | $2.9B | ||
| Q3 25 | $59.6M | $2.6B | ||
| Q2 25 | $63.5M | $2.7B | ||
| Q1 25 | $63.3M | $2.8B | ||
| Q4 24 | $60.2M | $3.0B | ||
| Q3 24 | $63.3M | $3.1B | ||
| Q2 24 | $60.8M | $3.3B | ||
| Q1 24 | $50.1M | — |
负债/权益比AMSGRAL
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 0.81× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-704.0K | $-63.8M |
| 自由现金流经营现金流 - 资本支出 | $-2.7M | $-63.9M |
| 自由现金流率自由现金流/营收 | -34.8% | -146.5% |
| 资本支出强度资本支出/营收 | 25.7% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.5M | $-299.9M |
8季度趋势，按日历期对齐
经营现金流AMSGRAL
| Q4 25 | $-704.0K | $-63.8M | ||
| Q3 25 | $1.7M | $-63.2M | ||
| Q2 25 | $-372.0K | $-77.0M | ||
| Q1 25 | $2.5M | $-95.0M | ||
| Q4 24 | $274.0K | — | ||
| Q3 24 | $472.0K | $-104.6M | ||
| Q2 24 | $1.3M | $-171.8M | ||
| Q1 24 | $-1.9M | $-207.3M |
自由现金流AMSGRAL
| Q4 25 | $-2.7M | $-63.9M | ||
| Q3 25 | $-2.0M | $-63.6M | ||
| Q2 25 | $-2.3M | $-77.3M | ||
| Q1 25 | $-1.5M | $-95.1M | ||
| Q4 24 | $-4.4M | — | ||
| Q3 24 | $-407.0K | $-105.6M | ||
| Q2 24 | $70.0K | $-173.2M | ||
| Q1 24 | $-3.0M | $-209.8M |
自由现金流率AMSGRAL
| Q4 25 | -34.8% | -146.5% | ||
| Q3 25 | -28.3% | -175.8% | ||
| Q2 25 | -32.1% | -217.6% | ||
| Q1 25 | -24.7% | -298.6% | ||
| Q4 24 | -48.4% | — | ||
| Q3 24 | -5.8% | -368.4% | ||
| Q2 24 | 1.0% | -541.7% | ||
| Q1 24 | -58.4% | -785.3% |
资本支出强度AMSGRAL
| Q4 25 | 25.7% | 0.2% | ||
| Q3 25 | 51.6% | 1.1% | ||
| Q2 25 | 26.9% | 1.0% | ||
| Q1 25 | 65.7% | 0.2% | ||
| Q4 24 | 51.4% | — | ||
| Q3 24 | 12.6% | 3.4% | ||
| Q2 24 | 17.2% | 4.3% | ||
| Q1 24 | 22.7% | 9.5% |
现金转化率AMSGRAL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.36× | — | ||
| Q1 24 | -15.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMS
| Direct Patient Services | $4.0M | 51% |
| Rental Income From Medical Services | $2.7M | 35% |
| Pbrt Services | $1.2M | 15% |
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
